ADH-1 is primarily used in cancer research and treatment, specifically targeting the inhibition of N-cadherin, a protein involved in cell adhesion. By blocking N-cadherin, ADH-1 disrupts the interactions between cancer cells and their surrounding environment, which can inhibit tumor growth and metastasis. It is often studied in combination with other therapies, such as chemotherapy, to enhance treatment efficacy. ADH-1 has shown promise in preclinical and clinical trials for treating various cancers, including melanoma and other solid tumors. Its ability to interfere with cell adhesion makes it a valuable tool in understanding and combating aggressive cancers.